References
- 1. Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer’s disease: Neurobiological links and common pharmacological targets. Eur J Pharmacol [Internet]. 2010;626(1):64–71.10.1016/j.ejphar.2009.10.02219837057
- 2. Vincent B. Protective roles of melatonin against the amyloid-dependent development of Alzheimer’s disease: A critical review. Pharmacol Res [Internet]. 2018;134(July):223–37.10.1016/j.phrs.2018.06.01129981776
- 3. Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E. Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171(15):3604–19.10.1111/bph.12720412806024724693
- 4. 4. Tchekalarova J, Stoynova T, Ilieva K, Mitreva R, Atanasova M. Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light. Pharmacol Biochem Behav. 2018;171:1-9.10.1016/j.pbb.2018.05.01629807067
- 5. Ilieva K, Tchekalarova J, Atanasova D, Kortenska L, Atanasova M. Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer’s disease in male rats. Horm Behav. 2019;107:11-9.10.1016/j.yhbeh.2018.11.00730452900
- 6. Balmus IM, Ciobica A, Antioch I, Dobrin R, Timofte D. Oxidative Stress Implications in the Affective Disorders: Main Biomarkers, Animal Models Relevance, Genetic Perspectives, and Antioxidant Approaches. Oxid Med Cell Longev. 2016;2016:(DD) 3975101.10.1155/2016/3975101498366927563374
- 7. Padurariu M, Antioch I, Balmus I, Ciobica A, El-Lethey HS, Kamel MM. Describing some behavioural animal models of anxiety and their mechanistics with special reference to oxidative stress and oxytocin relevance. Int J Vet Sci Med [Internet]. 2017;5(2):98–104.10.1016/j.ijvsm.2017.08.003613785630255057
- 8. Bild W, Ciobica A. Angiotensin-(1–7) central administration induces anxiolytic-like effects in elevated plus maze and decreased oxidative stress in the amygdala. J Affect Disord [Internet]. 2013;145(2):165–71.10.1016/j.jad.2012.07.02422868060
- 9. Bailey KR CJ. Anxiety-Related Behaviors in Mice. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis.; 2009. p. Chapter 5.
- 10. Unal G, Canbeyli R. Psychomotor retardation in depression: A critical measure of the forced swim test. Behav Brain Res [Internet]. 2019;372:112047.10.1016/j.bbr.2019.11204731255672
- 11. Yang J, Jin HJ, Mocaër E, Seguin L, Zhao H, Rusak B. Agomelatine affects rat suprachiasmatic nucleus neurons via melatonin and serotonin receptors. Life Sci [Internet]. 2016;155:147–54.10.1016/j.lfs.2016.04.03527269050
- 12. Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. Life Sci [Internet]. 2018;210:177–84.10.1016/j.lfs.2018.09.00330193943
- 13. Ho RC. Effects of different antidepressants on pro-inflammatory cytokines in rats undergoing chronic mild stress without lipopolysaccharide induction. J Psychosom Res [Internet]. 2015;78(6):602–3.10.1016/j.jpsychores.2015.03.057